Chardan Capital Has Bearish Outlook for FDMT FY2025 Earnings

Key Points

• Chardan Capital has significantly lowered its FY2025 EPS estimate for 4D Molecular Therapeutics from ($3.07) to ($3.52), despite maintaining a "Buy" rating on the stock with a price target of $25.00.
• The company reported a quarterly EPS of ($0.98), falling short of the consensus estimate of ($0.88) and generating a revenue of only $0.01 million compared to the expected $0.52 million.
• 4D Molecular Therapeutics' average rating is currently a "Moderate Buy" with a consensus price target of $30.40, however, the company faces several weakened price targets from various financial firms.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at Chardan Capital decreased their FY2025 earnings estimates for 4D Molecular Therapeutics in a research note issued on Tuesday, August 12th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($3.52) per share for the year, down from their previous forecast of ($3.07). Chardan Capital currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%.

Several other analysts also recently issued reports on FDMT. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday. Roth Capital dropped their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. The Goldman Sachs Group decreased their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Stock Up 0.1%

Shares of 4D Molecular Therapeutics stock traded up $0.01 on Friday, hitting $7.27. The stock had a trading volume of 1,204,970 shares, compared to its average volume of 2,463,474. The stock has a market cap of $339.51 million, a price-to-earnings ratio of -2.06 and a beta of 2.83. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $17.41. The business's 50 day moving average is $4.73 and its two-hundred day moving average is $4.14.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after purchasing an additional 1,337,497 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth $532,000. Two Sigma Investments LP boosted its stake in 4D Molecular Therapeutics by 196.3% in the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock valued at $1,749,000 after buying an additional 208,021 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in 4D Molecular Therapeutics in the first quarter valued at about $99,000. Finally, Wells Fargo & Company MN grew its position in 4D Molecular Therapeutics by 40.6% in the fourth quarter. Wells Fargo & Company MN now owns 25,852 shares of the company's stock valued at $144,000 after acquiring an additional 7,463 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.